These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3821622)

  • 1. Efficacy of aminohydroxypropylidene diphosphonate in the treatment of malignancy-associated hypercalcaemia.
    Stevens MJ
    Med J Aust; 1987 Mar; 146(5):261-4. PubMed ID: 3821622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
    Body JJ; Borkowski A; Cleeren A; Bijvoet OL
    J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
    Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL; Goa KL
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
    Ralston SH; Alzaid AA; Gardner MD; Boyle IT
    Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate.
    Tan TT; Alzaid AA; Sutcliffe N; Gardner MD; Thomson JA; Boyle IT
    Postgrad Med J; 1988 Mar; 64(749):224-7. PubMed ID: 3174541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.
    Cantwell BM; Harris AL
    Br Med J (Clin Res Ed); 1987 Feb; 294(6570):467-9. PubMed ID: 3103730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
    Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B
    Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases--a prospective randomised placebo-controlled multicentre study.
    Rotstein S; Glas U; Eriksson M; Pfeiffer P; Hansen J; Söderqvist J; Bandmann U; Strid S
    Eur J Cancer; 1992; 28A(4-5):890-3. PubMed ID: 1388038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of aminohydroxypropylidene diphosphonate on the bone metabolism of patients with parathyroid adenoma.
    Ishimura E; Miki T; Koyama H; Harada K; Nakatsuka K; Inaba M; Nishizawa Y; Morii H
    Horm Metab Res; 1993 Sep; 25(9):493-7. PubMed ID: 8225204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
    Jacobs TP; Siris ES; Bilezikian JP; Baquiran DC; Shane E; Canfield RE
    Ann Intern Med; 1981 Mar; 94(3):312-6. PubMed ID: 6452846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
    Coleman RE; Rubens RD
    Br J Cancer; 1987 Oct; 56(4):465-9. PubMed ID: 3689664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
    Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
    Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single high dose aminohydroxypropylidene diphosphonate infusions to treat cancer-associated hypercalcaemia.
    Cantwell B; Harris AL
    Lancet; 1986 Jan; 1(8473):165-6. PubMed ID: 2867388
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of malignant hypercalcaemia with clodronate.
    Percival RC; Paterson AD; Yates AJ; Beard DJ; Douglas DL; Neal FE; Russell RG; Kanis JA
    Br J Cancer; 1985 May; 51(5):665-9. PubMed ID: 3158326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypercalcemia in malignancies: treatment with dichloromethylene diphosphonate (Cl2MDP).
    Conte N; Di Virgilio R; Roiter I; Caberlotto L
    Tumori; 1985 Feb; 71(1):51-4. PubMed ID: 3157251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
    Mannix KA; Carmichael J; Harris AL; Cantwell BM
    Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
    Urwin GH; Yates AJ; Gray RE; Hamdy NA; McCloskey EV; Preston FE; Greaves M; Neil FE; Kanis JA
    Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD).
    Grutters JC; Hermus AR; de Mulder PH; Beex LV
    Breast Cancer Res Treat; 1993; 25(3):277-81. PubMed ID: 8369528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
    Chapuy MC; Meunier PJ; Alexandre CM; Vignon EP
    J Clin Invest; 1980 May; 65(5):1243-7. PubMed ID: 6444955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.